Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alkermes Plc (NASDAQ:ALKS)

55.74
Delayed Data
As of Jan 23
 -0.24 / -0.43%
Today’s Change
27.14
Today|||52-Week Range
60.74
+0.29%
Year-to-Date
BioCorRx Receives New Funding for Opioid Drug
Jan 22 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close55.98
Today’s open55.94
Day’s range55.04 - 56.50
Volume465,604
Average volume (3 months)1,080,854
Market cap$8.5B
Dividend yield--
Data as of 01/23/2017

Growth & Valuation

Earnings growth (last year)-623.81%
Earnings growth (this year)+34.06%
Earnings growth (next 5 years)+57.70%
Revenue growth (last year)+1.54%
P/E ratioNM
Price/Sales18.85
Price/Book6.42

Competitors

 Today’s
change
Today’s
% change
SGENSeattle Genetics Inc-0.27-0.46%
TSROTESARO Inc-0.91-0.62%
RDYDr.Reddy's Laborator...-0.34-0.78%
JAZZJazz Pharmaceuticals...-2.45-1.98%
Data as of 01/23/2017

Financials

Next reporting dateMarch 2, 2017
EPS forecast (this quarter)$0.03
Annual revenue (last year)$628.3M
Annual profit (last year)-$227.2M
Net profit margin-36.15%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Richard F. Pops
President
Shane M. Cooke
Corporate headquarters
Dublin, Dublin

Forecasts


Search for Jobs